UPDATE: Morgan Stanley Initiates Coverage On Infinity Pharmaceuticals On Data Upside Driver

In a report published Wednesday, Morgan Stanley analyst Matthew Harrison initiated coverage on

with an Overweight rating and $17.00 price target. In the report, Morgan Stanley noted, “Differentiated data in iNHL represents a viable path to market for Infinity's lead asset IPI-145 while strategic value and near-term data in RA / Asthma could offer paths to additional upside.” Infinity Pharmaceuticals closed on Tuesday at $11.89.